Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Vital-Net Aims at Sales Per MS of \150 million in FY2003
December 24, 2001
- Number of Clinical Trial Protocols Submitted Remains Flat: Korosho
December 24, 2001
- FALCO Biosystems Certified by CAP
December 24, 2001
- GL on Stroke Treatment Under Preparation: Seminar
December 24, 2001
- Main Reason for Merger Is to Add Value: Mr Burns of Roche
December 24, 2001
- Steroid Nasal Drops Effective against Japanese Cedar Pollinosis: GSK Seminar
December 24, 2001
- FPMAJ Proposes Fast Track System -1-
December 24, 2001
- Nearly 50% of Physicians Want Increased MTX Doses for RA: Society Meeting
December 24, 2001
- FPMAJ Proposes Fast Track System -2-
December 24, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
December 24, 2001
- Imigran Tablets Selling Better than Expected: GSK
December 24, 2001
- Health Minister Concerned About Higher Price of Reagent for Blood Test
December 24, 2001
- BUSINESS NEWS IN BRIEF
December 24, 2001
- Sanko Junyaku: Microplate EIA System
December 24, 2001
- Tanabe to Continue Strategic Technical Alliances with Foreign Companies
December 24, 2001
- Sysmex Develops Hemocytometer for POC Use
December 24, 2001
- 33 JPMA Member Companies: Sales Up 2.4%, Profits Up 56.5%
December 24, 2001
- Pharmacia to Spin Off Stake in Monsanto
December 24, 2001
- Morishita Jintan: Sales Up 3.7%, Net Profits Plummet
December 24, 2001
- Sysmex to Make International Reagents Its 100%-owned Subsidiary
December 24, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…